Andrew Berchuck

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 110:374-82. 2008
  2. pmc Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome
    Andrew Berchuck
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:2448-55. 2009
  3. ncbi request reprint Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers
    Andrew Berchuck
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Institute of Statistics and Decision Sciences, Center for Applied Genomics and Technology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 11:3686-96. 2005
  4. ncbi request reprint Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers
    Andrew Berchuck
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 13:2141-7. 2004
  5. doi request reprint Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium
    Andrew Berchuck
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Adv Exp Med Biol 622:53-67. 2008
  6. ncbi request reprint Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays
    Andrew Berchuck
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 190:910-25. 2004
  7. doi request reprint Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Int J Cancer 126:1378-89. 2010
  8. ncbi request reprint The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 107:285-91. 2007
  9. pmc Expression signatures of TP53 mutations in serous ovarian cancers
    Marcus Q Bernardini
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, 600 University Avenue, Toronto, Ontario M5G2M9, Canada
    BMC Cancer 10:237. 2010
  10. doi request reprint Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer
    Jason C Barnett
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA
    Am J Obstet Gynecol 205:143.e1-6. 2011

Research Grants

  1. Society of Gynecologic Investigation Annual Meeting
    Andrew Berchuck; Fiscal Year: 2007

Detail Information

Publications98

  1. doi request reprint Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 110:374-82. 2008
    ....
  2. pmc Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome
    Andrew Berchuck
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:2448-55. 2009
    ..In the present study, we report on gene expression of early-stage cancers and validate our prognostic model for advanced-stage cancers...
  3. ncbi request reprint Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers
    Andrew Berchuck
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Institute of Statistics and Decision Sciences, Center for Applied Genomics and Technology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 11:3686-96. 2005
    ..The objective of this study was to define gene expression patterns associated with favorable survival...
  4. ncbi request reprint Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers
    Andrew Berchuck
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 13:2141-7. 2004
    ..In this study, we sought to determine whether this polymorphism affects ovarian cancer risk...
  5. doi request reprint Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium
    Andrew Berchuck
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Adv Exp Med Biol 622:53-67. 2008
  6. ncbi request reprint Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays
    Andrew Berchuck
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 190:910-25. 2004
    ..The purpose of this study was to define gene expression patterns that are associated with the optimal versus suboptimal debulking of advanced-stage serous ovarian cancers...
  7. doi request reprint Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Int J Cancer 126:1378-89. 2010
    ..04). MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer...
  8. ncbi request reprint The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 107:285-91. 2007
    ..We sought to determine the outcome of patients with advanced stage endometrial cancer treated with postoperative chemotherapy+/-radiation to determine whether there was an advantage to combining treatment modalities...
  9. pmc Expression signatures of TP53 mutations in serous ovarian cancers
    Marcus Q Bernardini
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, 600 University Avenue, Toronto, Ontario M5G2M9, Canada
    BMC Cancer 10:237. 2010
    ..Mutations in the TP53 gene are extremely common and occur very early in the progression of serous ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and biology of the disease...
  10. doi request reprint Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer
    Jason C Barnett
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA
    Am J Obstet Gynecol 205:143.e1-6. 2011
    ..The objective of the study was to compare adverse event rates between laparoscopic vs open surgery for endometrial cancer...
  11. ncbi request reprint Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer
    Robert M Wenham
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Soc Gynecol Investig 10:381-7. 2003
    ..The 2G allele also has been associated with increased MMP1 expression. We investigated the relationship between the MMP1 polymorphism and ovarian cancer risk in a large population-based, case-control study...
  12. doi request reprint Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study
    Jennifer M Rubatt
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:469-74. 2009
    ..The aims of this study were to examine prognostic significance of microvessel density (MVD) in previously-untreated, advanced epithelial ovarian cancer (EOC) and explore associations between MVD and factors that affect angiogenesis...
  13. ncbi request reprint Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer
    Joellen M Schildkraut
    Department of Community and Family Medicine, Duke University Medical Center, Box 2949, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 16:473-80. 2007
    ..Two trinucleotide repeat polymorphisms have been described in exon 1 of the androgen receptor (AR) gene that may affect its function. Previous studies of ovarian cancer and AR repeat polymorphisms have been inconsistent...
  14. ncbi request reprint Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer
    Robert M Wenham
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:4396-403. 2003
    ..We have examined whether BRCA2 N372H or common amino acid-changing polymorphisms in BRCA1 predispose to ovarian cancer...
  15. ncbi request reprint Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 3079, Duke University Medical Center, Durham, NC 27710, USA
    Int J Clin Oncol 12:31-6. 2007
    ..The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies...
  16. pmc A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
    Clin Cancer Res 18:5489-98. 2012
    ..We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in the treatment of advanced and recurrent epithelial ovarian cancer...
  17. ncbi request reprint Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma
    Ellen Jones
    Department of Radiation Oncology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Hyperthermia 22:161-72. 2006
    ..These promising results suggest a role for the use of adjuvant whole abdomen hyperthermia as a means of augmenting chemosensitization...
  18. doi request reprint A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 118:3283-93. 2012
    ..The aim of this randomized clinical trial was to evaluate the efficacy and safety of combination (cDC) and sequential (sDC) weekly docetaxel and carboplatin in women with recurrent platinum-sensitive epithelial ovarian cancer (EOC)...
  19. pmc Yin yang 1 modulates taxane response in epithelial ovarian cancer
    Noriomi Matsumura
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Mol Cancer Res 7:210-20. 2009
    ....
  20. ncbi request reprint The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 104:401-5. 2007
    ..We sought to determine whether recurrence and survival of patients with stage IIIA endometrial cancer differ with surgical pathologic findings (positive peritoneal cytology versus positive adnexae or serosa) and adjuvant treatment...
  21. pmc Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women
    Patricia G Moorman
    Department of Community and Family Medicine, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, NC 27705, USA
    Am J Epidemiol 167:1059-69. 2008
    ..Findings suggest that associations between ovarian cancer and reproductive characteristics vary by menopausal status. Additional research is needed to further elucidate risk factors for postmenopausal disease...
  22. ncbi request reprint Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    Box 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 101:390-7. 2006
    ..This study examined MASPIN expression in human ovarian cancer, and explored the association between MASPIN and prognosis in patients with advanced stage disease treated with first-line cisplatin, carboplatin and/or paclitaxel...
  23. ncbi request reprint Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas
    Jay E Allard
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and the United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC, USA
    Gynecol Oncol 107:52-7. 2007
    ..Since FOLR1 overexpression is a frequent event in some types of endometrial carcinoma, we examined the relationship between FOLR1 overexpression and clinical and pathologic features to determine its prognostic relevance...
  24. ncbi request reprint Gene expression patterns that characterize advanced stage serous ovarian cancers
    Johnathan M Lancaster
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Soc Gynecol Investig 11:51-9. 2004
    ..To identify gene expression patterns that characterize advanced stage serous ovarian cancers by using microarray expression analysis...
  25. doi request reprint Targeting slow-proliferating ovarian cancer cells
    Eiji Kondoh
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University, Durham, NC 27708, USA
    Int J Cancer 126:2448-56. 2010
    ..002; overall survival, p = 0.04). These results suggest that targeting quiescent ovarian cancer cells may be a worthwhile therapeutic approach to improving survival of women with ovarian cancer...
  26. pmc Regulation of the metastasis suppressor gene MKK4 in ovarian cancer
    Monique A Spillman
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 105:312-20. 2007
    ..We sought to investigate whether promoter methylation, loss of heterozygosity, or changes in phosphorylation are involved in MKK4 dysregulation during ovarian carcinogenesis...
  27. ncbi request reprint Resection of lymph node metastases influences survival in stage IIIC endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 99:689-95. 2005
    ..Our objective was to compare survival of patients who underwent resection of grossly positive lymph nodes (LN) to those with microscopically positive LN...
  28. doi request reprint Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup
    Joellen M Schildkraut
    Department of Community and Family Medicine, Duke University Medical Center, Box 2949, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 17:585-93. 2008
    ..The objective of this study was to determine whether cyclin E overexpression defines an etiologically distinct subgroup of ovarian cancer...
  29. pmc Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer
    Joellen M Schildkraut
    Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 5:e10061. 2010
    ....
  30. pmc Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer
    Noriomi Matsumura
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Genome Res 21:74-82. 2011
    ..These data suggest that accumulation of age-related epigenetic modifications leads to suppression of TGF-beta signaling and contributes to ovarian carcinogenesis...
  31. doi request reprint Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group s
    Elizabeth L Jewell
    Duke University Medical Center 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 115:424-9. 2009
    ....
  32. ncbi request reprint Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk
    Monique A Spillman
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University, DUMC Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 97:543-9. 2005
    ..It has been suggested that the 6A allele of the type I TGFbeta receptor (TGFbetaR1) polyalanine repeat tract polymorphism may increase susceptibility to various types of cancer including ovarian cancer...
  33. doi request reprint Transcript expression in endometrial cancers from Black and White patients
    G Larry Maxwell
    Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church VA 22042, USA
    Gynecol Oncol 130:169-73. 2013
    ..The objective of this investigation was to determine whether gene expression among endometrial cancers is different between Blacks and Whites...
  34. doi request reprint Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women
    Delores J Grant
    Department of Biology and Cancer Research Program, JLC Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC, USA
    Gynecol Oncol 129:173-8. 2013
    ..Polymorphisms in the vitamin D receptor (VDR) gene have been shown in some studies to be associated with the risk of epithelial ovarian cancer (EOC) in Caucasian women. There are no published reports among African Americans...
  35. ncbi request reprint No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina
    Johnathan M Lancaster
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Epidemiol Biomarkers Prev 12:226-7. 2003
  36. ncbi request reprint Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer
    Janiel M Cragun
    Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    J Clin Oncol 23:3668-75. 2005
    ..Our goal was to assess effects of the extent of selective lymphadenectomy on outcomes in women with apparent stage I endometrial cancer at laparotomy...
  37. doi request reprint The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer
    Junzo P Chino
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 82:1872-9. 2012
    ..We explored the impact of specific RT modalities (whole pelvic RT [WPRT], vaginal brachytherapy [VB]) and LND status on survival...
  38. ncbi request reprint Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer
    Susan K Murphy
    Division of Gynecologic Oncology, Duke University Medical Center, Box 91012, Durham, NC 27708, USA
    Mol Cancer Res 4:283-92. 2006
    ..These data indicate that the epigenetic changes observed in these cancers at the imprint center may contribute to IGF2 overexpression in a novel mechanistic manner...
  39. pmc Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer
    Joellen M Schildkraut
    Comprehensive Cancer Center, Department of Community and Family Medicine, Duke University Medical Center, and Department of Statistical Science, Duke University, Durham, North Carolina, USA
    Cancer Res 69:2349-57. 2009
    ..This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region...
  40. doi request reprint Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 122:467-72. 2011
    ..To evaluate the costs and effectiveness of thromboprophylaxis strategies following laparotomy for ovarian cancer...
  41. ncbi request reprint Outcomes in surgical stage I uterine papillary serous carcinoma
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 105:677-82. 2007
    ..The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine whether outcomes of women with surgical stage I UPSC differ with and without adjuvant therapy...
  42. doi request reprint Relationship between tamoxifen use and high risk endometrial cancer histologic types
    Amy E Bland
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:150-4. 2009
    ....
  43. ncbi request reprint Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    DUMC 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 106:221-32. 2007
    ....
  44. pmc Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues
    Gregory P Sfakianos
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 129:159-64. 2013
    ..The aim of this study was to determine if gene expression signatures can be translated to fixed archival tissues...
  45. doi request reprint Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:386-91. 2012
    ..The objective of the current study was to construct a cost-utility model to compare these 2 regimens with the incorporation of prospectively collected quality-of-life (QoL) data...
  46. pmc Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells
    Deanna Teoh
    Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Gynecol Oncol 121:187-92. 2011
    ..To explore the activity of dasatinib alone and in combination with paclitaxel and carboplatin in ovarian cancer cells and to determine if dasatinib activity can be predicted based on evaluation of the SRC pathway...
  47. doi request reprint Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype
    Jason C Barnett
    Division of Gynecologic Oncology Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 116:556-62. 2010
    ..The objective of this study was to examine the clinicopathologic correlates of T-regulatory (T(reg)) cell infiltration in serous ovarian cancers and to define gene signatures associated with high T(reg)s...
  48. doi request reprint Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer
    Amy E Bondurant
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Gynecol Oncol 123:581-7. 2011
    ....
  49. ncbi request reprint Antidepressant medication use [corrected] and risk of ovarian cancer
    Patricia G Moorman
    Cancer Prevention, Detection, and Control Research Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Obstet Gynecol 105:725-30. 2005
    ..The objective of this paper was to evaluate whether women with ovarian cancer were more likely to report past use of antidepressants than control women...
  50. ncbi request reprint Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women
    Cathrine Hoyo
    Department of Community and Family Medicine, Duke University Medical Center, 2424 Erwin Rd, Hock Plaza, Ste 602, Durham, NC 27710, USA
    Cancer Causes Control 16:955-63. 2005
    ..0; 95% CI = 0.7-1.4). These findings support the hypothesis that obesity is an important risk factor of ovarian cancer among African-Americans and Whites and also suggest that height may be a risk factor specific to African-Americans...
  51. ncbi request reprint Analgesic drug use and risk of ovarian cancer
    Joellen M Schildkraut
    Duke Comprehensive Cancer Center, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Epidemiology 17:104-7. 2006
    ..Previous epidemiologic research suggests that analgesic use may reduce the risk of ovarian cancer, although results are not consistent...
  52. doi request reprint Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer
    Micael Lopez-Acevedo
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 130:156-61. 2013
    ....
  53. pmc Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers
    William J Lowery
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina 27710, USA
    Int J Gynecol Cancer 22:9-14. 2012
    ....
  54. ncbi request reprint Menopausal hormones and risk of ovarian cancer
    Patricia G Moorman
    Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 193:76-82. 2005
    ..The objective of this study was to determine if use of menopausal hormones was associated with ovarian cancer and if risk varied by type of hormone used...
  55. pmc Ovarian cancer risk factors in African-American and white women
    Patricia G Moorman
    Duke University Medical Center, 2424 Erwin Road, Suite 602, Durham, NC 27705, USA
    Am J Epidemiol 170:598-606. 2009
    ..There is a clear need for further research on etiologic factors for ovarian cancer in African-American women...
  56. ncbi request reprint Genomic signatures to guide the use of chemotherapeutics
    Anil Potti
    Duke Institute for Genome Sciences and Policy, Duke University, Box 3382, Durham, North Carolina 27710, USA
    Nat Med 12:1294-300. 2006
    ..The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies...
  57. ncbi request reprint Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Andrea H Bild
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Nature 439:353-7. 2006
    ..Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics...
  58. doi request reprint Evaluation of two management strategies for preoperative grade 1 endometrial cancer
    Marcus Q Bernardini
    Division of Gynaecologic Oncology, University Health Network, Toronto, Ontario, Canada
    Obstet Gynecol 114:7-15. 2009
    ..To compare the practices, adjuvant treatment, and outcomes of patients with preoperatively assessed grade 1 endometrioid endometrial cancer between two academic gynecologic oncology centers that use different treatment strategies...
  59. pmc Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program
    Paula S Lee
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    JSLS 13:467-72. 2009
    ..Our goal was to perform an early evaluation of the feasibility of training fellows in robotic-assisted gynecologic procedures at the outset of our incorporation of this technology into clinical practice...
  60. ncbi request reprint Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma
    Louis A Dainty
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and the United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Gynecol Oncol 105:563-70. 2007
    ..The purpose of this study was to examine the expression of FOLR1 in uterine cancers and to identify changes in gene expression that are associated with overexpression of FOLR1...
  61. doi request reprint Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells
    Gustavo C Rodriguez
    Division of Gynecologic Oncology, NorthShore University Healthsystem, Evanston, IL 60201, USA
    Am J Obstet Gynecol 206:253.e1-9. 2012
    ..Because both induce apoptosis, we investigated the potential for synergistic impact of combined drug treatment on cell death...
  62. ncbi request reprint Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls
    Marilyn F Vine
    Cancer Prevention, Detection and Control Research Program, Box 2949, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 90:75-82. 2003
    ..The goal of this study was to characterize types, frequency, combinations, and relative onset of symptoms among ovarian cancer cases and controls...
  63. doi request reprint Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer
    Jonathan S Berek
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Women s Cancer Center, Stanford Cancer Center, Stanford, California, USA
    Obstet Gynecol 116:733-43. 2010
    ..Conversely, women at high risk of ovarian cancer should undergo risk-reducing bilateral salpingo-oophorectomy...
  64. ncbi request reprint High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival
    Johnathan M Lancaster
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27720, USA
    Clin Cancer Res 9:762-6. 2003
    ..We therefore sought to confirm the association between TRAIL expression and survival in a larger group of women with ovarian cancer...
  65. ncbi request reprint Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)
    Patricia G Moorman
    Cancer Prevention, Detection, and Control Research Program, Department of Community and Family Medicine, Duike Universiti Medical Center, Durham, NC 27710, USA
    Cancer Causes Control 13:807-11. 2002
    ..To compare two methods for calculating lifetime ovulatory cycles (LOC) to determine if more detailed menstrual cycle information results in stronger associations with ovarian cancer...
  66. ncbi request reprint The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 94:74-9. 2004
    ....
  67. pmc High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer
    Zhiqing Huang
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27708, USA
    Nucleic Acids Res 34:555-63. 2006
    ..They further show that the methylation status of the intron 2 CpG island may be a useful indicator of LOH and biomarker of disease...
  68. ncbi request reprint Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study
    Laura Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 21:3814-25. 2003
    ..The prognostic significance of p53 mutations and overexpression in advanced epithelial ovarian cancers was examined in primary tumors from 125 patients participating in a Gynecologic Oncology Group randomized phase III treatment protocol...
  69. ncbi request reprint Predictors of clinical outcomes in the laparoscopic management of adnexal masses
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
    Obstet Gynecol 102:243-51. 2003
    ..Laparoscopy has become an accepted approach in the management of adnexal masses. We evaluated clinical outcomes of laparoscopic management of adnexal masses thought to be benign preoperatively...
  70. doi request reprint High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer
    Jason C Barnett
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology and Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Obstet Gynecol 115:49-54. 2010
    ..To estimate the range of poly(adenosine diphosphate [ADP]-ribose) polymerase expression in serous ovarian cancers and to determine whether expression is associated with response to therapy and outcome...
  71. doi request reprint Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 117:545-53. 2011
    ..The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies...
  72. ncbi request reprint A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma
    Ellen L Jones
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 98:277-82. 2003
    ..The authors evaluated response and toxicity in patients with locally advanced cervical carcinoma (LACC) who were treated with concurrent weekly CDDP, HT, and RT (whole pelvis [n=7] and whole pelvis and paraaortic nodes [n=5])...
  73. ncbi request reprint Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity
    John T Soper
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 97:596-601. 2005
    ..To compare flap-specific complications of rectus abdominis myocutaneous (RAM) and myoperitoneal (RAMP) flap neovagina reconstructions performed concurrently with radical pelvic procedures...
  74. doi request reprint Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation
    G Larry Maxwell
    Division of Gynecologic Oncology, Walter Reed Army Medical Center, 6900 Georgia Avenue, Washington DC 20307, USA
    Gynecol Oncol 121:586-94. 2011
    ..The present study aimed to identify differentially expressed proteins employing a high resolution mass spectrometry (MS)-based proteomic analysis of endometrial cancer cells harvested using laser microdissection...
  75. ncbi request reprint Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 88:51-7. 2003
    ..Combination paclitaxel and carboplatin is a well-established first-line regimen for ovarian cancer. The purpose of this study was to evaluate weekly low-dose paclitaxel and carboplatin in recurrent ovarian or peritoneal cancer...
  76. ncbi request reprint The role of PET scanning in the detection of recurrent cervical cancer
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 90:186-90. 2003
    ..Little is known about the efficacy of PET for detecting recurrent disease. We evaluated the potential role of FDG PET in the context of suspected recurrent cervical cancer...
  77. ncbi request reprint The role of genetic testing for cancer susceptibility in gynecologic practice
    Beth Y Karlan
    Women s Cancer Research Institute, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of Los Angeles, Los Angeles, California 90048, USA
    Obstet Gynecol 110:155-67. 2007
    ..Practical applications of genetic testing for cancer susceptibility have the ability to reduce the burden of hereditary cancers by saving lives, decreasing medical morbidities, and reducing psychological stress...
  78. ncbi request reprint Molecular aspects of ovarian cancer
    Robert M Wenham
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Best Pract Res Clin Obstet Gynaecol 16:483-97. 2002
    ..Hopefully, this knowledge can be translated into effective screening, treatment, surveillance, and prevention strategies in the future...
  79. ncbi request reprint Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta
    Gustavo C Rodriguez
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
    J Natl Cancer Inst 94:50-60. 2002
    ..We determined the effect of progestin on TGF-beta expression in the primate ovarian epithelium and examined the relationship between TGF-beta expression and apoptosis...
  80. ncbi request reprint Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer
    G Larry Maxwell
    Division of Gynecologic Oncology Walter Reed Army Medical Center, Washington, DC 20307, USA
    Clin Cancer Res 11:4056-66. 2005
    ..An understanding of the molecular heterogeneity of various histologic types of endometrial cancer has the potential to lead to better individualization of treatment in the future...
  81. ncbi request reprint BRAF polymorphisms and the risk of ovarian cancer of low malignant potential
    Livia Kelemen
    Queensland Institute of Medical Research, 300 Herston Rd, Herston, QLD 4006, Australia
    Gynecol Oncol 97:807-12. 2005
    ..6%. We therefore hypothesized that the same BRAF haplotype may confer an increased risk of serous ovarian tumors of low malignant potential...
  82. ncbi request reprint Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer
    Janos L Tanyi
    Departments of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3534-45. 2003
    ..Thus, the LPA-rich environment of the ovarian cancer cell in vivo and the subsequent effects of cellular pathophysiology may be a consequence of both increased LPA production and decreased LPA metabolism by ovarian cancer cells...
  83. pmc Consortium analysis of 7 candidate SNPs for ovarian cancer
    Susan J Ramus
    Translational Research Laboratory, University College London EGA Institute for Women s Health, London, United Kingdom
    Int J Cancer 123:380-8. 2008
    ..These null results for SNPs identified from relatively large initial studies shows the importance of replicating associations by a consortium approach...
  84. ncbi request reprint High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer
    Robyn A Sayer
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MCC GYNPROG, Tampa, FL 33612 9497, USA
    Gynecol Oncol 96:355-61. 2005
    ..The purpose of the current study is to further elucidate the role of the IGF-2 gene in ovarian cancer development and progression...
  85. ncbi request reprint Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions
    Steven J Skates
    Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, USA
    J Clin Oncol 22:4059-66. 2004
    ..For direct comparisons between marker panels, all sensitivity results correspond to a 98% fixed first-line specificity (referral rate 2%)...
  86. ncbi request reprint Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer
    Zhen Zhang
    Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 64:5882-90. 2004
    ..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer...
  87. ncbi request reprint Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
    Karen H Lu
    Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3291-300. 2004
    ..Consequently, use of multiple markers in combination might detect a larger fraction of early-stage ovarian cancers...
  88. ncbi request reprint Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling
    John I Risinger
    Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Res 65:5031-7. 2005
    ..These data classify histologically similar endometrioid endometrial cancers into two distinct groupings with implications affecting therapy and prevention...
  89. ncbi request reprint Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon
    Rebecca T Marquez
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6116-26. 2005
    ..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble...
  90. ncbi request reprint Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology
    Christopher V Lutman
    Riverside Gynecologic Oncology, Columbus, OH 43214, USA
    Gynecol Oncol 102:92-7. 2006
    ..To determine whether pelvic lymph node count is associated with patterns of recurrence or survival in patients with FIGO stage I and II endometrial cancer...
  91. ncbi request reprint Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability
    John I Risinger
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Biomark 2:61-8. 2006
    ..These data indicate that significant differences in TIL derived transcripts do not occur between endometrioid endometrial cancers with and without microsatellite instability...
  92. ncbi request reprint Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression
    John Ian Risinger
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 13:1713-9. 2007
    ..The purpose of this study was to identify those CT genes with the greatest incidence of expression in uterine cancers...
  93. ncbi request reprint An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer
    Holly K Dressman
    Division of Gynecologic Surgical Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 25:517-25. 2007
    ..We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease...
  94. ncbi request reprint Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer
    Simon A Gayther
    Translational Research Laboratories, University College London, London, United Kingdom
    Cancer Res 67:3027-35. 2007
    ..This study highlights the need for multicenter collaborations for genetic association studies...
  95. pmc Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer
    Zhen Zhang
    Center for Biomarker Discovery, Department of Pathology, Johns Hopkins Medical Institutions, CRB II 3M04, 1550 Orleans Street, Baltimore, MD 21231, USA
    Gynecol Oncol 107:526-31. 2007
    ..In this paper, an ANN model was evaluated for its performance in detecting early stage epithelial ovarian cancer using multiple serum markers...
  96. ncbi request reprint Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions
    Johnathan M Lancaster
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Gynecol Oncol 107:159-62. 2007
    ..This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome...
  97. ncbi request reprint Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray
    Michael A Bidus
    Walter Reed Army Medical Center and the United States Military Cancer Institute, Washington, DC 20307, USA
    Clin Cancer Res 12:83-8. 2006
    ..To characterize the gene expression profiles of endometrioid endometrial cancers associated with lymph node metastasis in an effort to identify genes associated with metastatic spread...
  98. ncbi request reprint Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer
    John I Risinger
    Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 63:6-11. 2003
    ..These data provide the basis for investigation of previously unrecognized novel pathways involved in the development of endometrial cancers...

Research Grants2

  1. Society of Gynecologic Investigation Annual Meeting
    Andrew Berchuck; Fiscal Year: 2007
    ..It is hoped that this initiative will stimulate greater interest in cancer research by those early in their careers, and will enhance the scientific exchange and collaboration of more senior investigators. ..